US Patent

US8114909 — Treating or preventing restless legs syndrome using prodrugs of GABA analogs

Method of Use · Assigned to XenoPort Inc · Expires 2026-04-11 · 0y expired

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of using prodrugs of GABA analogs to treat or prevent restless legs syndrome in humans.

USPTO Abstract

Disclosed herein are methods of using prodrugs of gamma aminobutyric acid (GABA) analogs and pharmaceutical compositions thereof to treat or prevent restless legs syndrome in humans, and pharmaceutical compositions of prodrugs of GABA analogs useful in treating or preventing restless legs syndrome.

Drugs covered by this patent

Horizant (GABAPENTIN ENACARBIL) · Azurity

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1231`	—	Horizant
`U-1231`	—	Horizant

Patent Metadata

Patent number: US8114909
Jurisdiction: US
Classification: Method of Use
Expires: 2026-04-11
Drug substance claim: No
Drug product claim: No
Assignee: XenoPort Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.